Treatment duration and long-term outcomes with daratumumab in transplant-ineligible newly diagnosed multiple myeloma from the phase 3 MAIA study

被引：0
|
作者：
Moreau, Philippe [1 ]
Facon, Thierry [2 ]
Usmani, Saad [3 ]
Kumar, Shaji [4 ]
Plesner, Torben [5 ,6 ]
Goldschmidt, Hartmut [7 ,8 ]
Orlowski, Robert [9 ]
Perrot, Aurore [10 ]
Chari, Ajai [11 ]
Cook, Gordon [12 ]
Pei, Huiling [13 ]
Van Rampelbergh, Rian [14 ]
Bartlett, J. Blake [15 ]
Uhlar, Clarissa [16 ]
Carson, Robin [16 ]
Bahlis, Nizar [17 ]
机构：
[1] Univ Hosp Hotel Dieu, Dept Hematol, Nantes, France
[2] Univ Lille, CHU Lille, Serv Malad Sang, Lille, France
[3] Mem Sloan Kettering Canc Ctr, New York, NY USA
[4] Mayo Clin Rochester, Dept Hematol, Rochester, MN USA
[5] Vejle Hosp, Vejle, Denmark
[6] Univ Southern Denmark, Vejle, Denmark
[7] Univ Hosp Heidelberg, Internal Med 5, Heidelberg, Germany
[8] Natl Ctr Tumor Dis NCT, Heidelberg, Germany
[9] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX USA
[10] Inst Univ Canc Toulouse Oncopole, Toulouse, France
[11] Icahn Sch Med Mt Sinai, New York, NY USA
[12] Leeds Inst Clin Trials Res, Leeds Canc Res UK CTU, Leeds, W Yorkshire, England
[13] Janssen Res & Dev LLC, Titusville, NJ USA
[14] Janssen Res & Dev, Beerse, Belgium
[15] Janssen Res & Dev LLC, Raritan, NJ USA
[16] Janssen Res & Dev LLC, Spring House, PA USA
[17] Univ Calgary, Calgary, AB, Canada
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2022年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OAB-039
引用
收藏
页码：S23 / S24
页数：2
相关论文
共 50 条
  • [31] Impact of age on efficacy and safety of daratumumab in combination with lenalidomide and dexamethasone (D-Rd) in patients (pts) with transplant-ineligible newly diagnosed multiple myeloma (NDMM): MAIA.
    Usmani, Saad Zafar
    Facon, Thierry
    Kumar, Shaji
    Plesner, Torben
    Moreau, Philippe
    Basu, Supratik
    Nahi, Hareth
    Macro, Margaret
    Quach, Hang
    Perrot, Aurore
    Venner, Chris
    Weisel, Katja
    Raje, Noopur S.
    Attal, Michel
    Leleu, Xavier
    Krevvata, Maria
    Wang, Jianping
    Kobos, Rachel
    Hulin, Cyrille
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [32] Chronological age as a prognostic factor in transplant-ineligible patients with newly diagnosed Multiple Myeloma
    Garcia Ruiz, Raquel
    Meseguer Martinez, Elena
    Navarro Vicente, Irene
    Jimenez Castillo, Maria
    Orti Verdet, Maria Consejo
    Frances Aracil, Eva
    Arnao Herraiz, Mario
    Cortes Ortega, Omara Samantha
    Solves Alcaina, Pilar
    Cejalvo Andujar, Maria Jose
    Andreu de la Piedra, Rafael
    Garcia Feria, Ana
    Ribas Garcia, Maria Paz
    de la Rubia, Javier
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S126 - S126
  • [33] Ixazomib or Lenalidomide combined with cyclophosphamide and dexamethasone in the treatment of elderly transplant-ineligible newly diagnosed multiple myeloma
    Wang, Yan
    Liu, Yuan-Fang
    Jin, Shi-Wei
    Tao, Yi
    Zhang, Wei-Ping
    Chen, Jian-Lin
    Jiang, Song-Fu
    Mi, Jian-Qing
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [34] Patient-reported outcomes with daratumumab, lenalidomide, and dexamethasone in frail transplant-ineligible patients from MAIA
    Ramasamy, Karthik
    Facon, Thierry
    Plesner, Torben
    Usmani, Saad
    Kumar, Shaji
    Bahlis, Nizar
    Hulin, Cyrille
    Orlowski, Robert
    Nahi, Hareth
    Mollee, Peter
    Perrott, Aurore
    Jaccard, Arnaud
    Delforge, Michael
    Karlin, Lionel
    Arnulf, Bertrand
    Chari, Ajai
    Pei, Huiling
    Gupta, Niodita
    Kaila, Shuchita
    Matt, Kathryn
    Gries, Katharine
    Carson, Robin
    Borgsten, Fredrik
    Weisel, Katja
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 69 - 70
  • [35] Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study
    Moreau, Philippe
    Facon, Thierry
    Usmani, Saad
    Bahlis, Nizar Jacques
    Raje, Noopur
    Plesner, Torben
    Orlowski, Robert Z.
    Basu, Supratik
    Nahi, Hareth
    Hulin, Cyrille
    Quach, Hang
    Goldschmidt, Hartmut
    O'Dwyer, Michael
    Perrot, Aurore
    Venner, Christopher P.
    Weisel, Katja
    Tiab, Mourad
    Macro, Margaret
    Frenzel, Laurent
    Leleu, Xavier
    Pei, Huiling
    Krevvata, Maria
    Carson, Robin
    Borgsten, Fredrik
    Kumar, Shaji K.
    BLOOD, 2022, 140 : 7297 - 7300
  • [36] Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients (Pts) With Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 MAIA Study
    Moreau, P.
    Facon, T.
    Usmani, S. Z.
    Bahlis, N.
    Raje, N.
    Plesner, T.
    Orlowski, R. Z.
    Basu, S.
    Nahi, H.
    Hulin, C.
    Quach, H.
    Goldschmidt, H.
    O'Dwyer, M.
    Perrot, A.
    Venner, C. P.
    Weisel, K.
    Tiab, M.
    Macro, M.
    Frenzel, L.
    Leleu, X.
    Wang, G.
    Krevvata, M.
    Carson, R.
    Borgsten, F.
    Kumar, S. K.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 238 - 238
  • [37] Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma
    Facon, Thierry
    Venner, Christopher P.
    Bahlis, Nizar J.
    Offner, Fritz
    White, Darrell J.
    Karlin, Lionel
    Benboubker, Lotfi
    Rigaudeau, Sophie
    Rodon, Philippe
    Voog, Eric
    Yoon, Sung-Soo
    Suzuki, Kenshi
    Shibayama, Hirohiko
    Zhang, Xiaoquan
    Twumasi-Ankrah, Philip
    Yung, Godwin
    Rifkin, Robert M.
    Moreau, Philippe
    Lonial, Sagar
    Kumar, Shaji K.
    Richardson, Paul G.
    Rajkumar, S. Vincent
    BLOOD, 2021, 137 (26) : 3616 - 3628
  • [38] Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients (Pts) With Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 MAIA Study
    Moreau, P.
    Facon, T.
    Usmani, S. Z.
    Bahlis, N.
    Raje, N.
    Plesner, T.
    Orlowski, R. Z.
    Basu, S.
    Nahi, H.
    Hulin, C.
    Quach, H.
    Goldschmidt, H.
    O'Dwyer, M.
    Perrot, A.
    Venner, C. P.
    Weisel, K.
    Tiab, M.
    Macro, M.
    Frenzel, L.
    Leleu, X.
    Pei, H.
    Krevvata, M.
    Carson, R.
    Borgsten, F.
    Kumar, S. K.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 316 - 317
  • [39] Overall survival (OS) results with Daratumumab (DARA), Lenalidomide and Dexamethasone (D-Rd) Vs Lenalidomide and Dexamethasone (Rd) in transplant-ineligible newly diagnosed multiple myeloma (TIE-NDMM): Phase 3 MAIA study
    Weisel, K.
    Facon, T.
    Kumar, S.
    Plesner, T.
    Orlowski, R. Z.
    Moreau, P.
    Bahlis, N.
    Basu, S.
    Nahi, H.
    Hulin, C.
    Quach, H.
    Goldschmidt, H.
    O'Dwyer, M.
    Perrot, A.
    Venner, C. P.
    Mace, J. R.
    Raje, N.
    Tiab, M.
    Macro, M.
    Frenzel, L.
    Leleu, X.
    Ahmadi, T.
    Wang, J.
    Rampelbergh, R., V
    Uhlar, C. M.
    Tromp, B.
    Delioukina, M.
    Vermeulen, J.
    Usmani, S. Z.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 184 - 185
  • [40] A glimpse into transplant-ineligible newly diagnosed multiple myeloma treatment in real-world practice in Spain: carinae study
    de Arriba de la Fuente, Felipe
    Hernandez Garcia, Miguel Teodoro
    Soler Campos, Juan Alfons
    Herraez Rodriguez, Susana
    Jose Moreno, Ma
    Conzalez Pardo, Miriam
    Gironella Mesa, Mercedes
    Casanova Espinosa, Maria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S143 - S144
12345